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Abstract
Background: Antibodies to the heparin-platelet factor-4 (HPF-4) complex (HIT antibodies) have
been observed in patients with heparin-induced thrombocytopenia (HIT). These antibodies are
thought to be involved in thrombosis through activation of platelet/endothelial cells. This
prospective study was conducted to determine the incidence of post-operative HIT antibodies to
assess the associated risk of deep vein thrombosis (DVT) in patients undergoing total knee
arthroplasty (TKA) or total hip arthroplasty (THA).
Methods: We studied 104 patients who underwent unilateral primary TKA (n = 44) and primary
THA (n = 60) with short-duration prophylaxis (1–2 days of a fixed dose of unfractionated heparin).
HIT antibodies were assayed using a sandwich-type ELISA before the operation and after heparin
treatment (post-operative day 7).
Results: In the clinical outcome, the incidence of symptomatic DVT was 15.4% (16/104, TKA; 10,
THA 6) and pulmonary embolism (PE) was not observed. The total seroconversion rate of HIT
antibodies at post-operative day 7 was 34.6% (36/104). Among 36 seroconverted patients, 11
(30.6%) developed symptomatic DVT and 5 out of 68 of the non-seroconverted patients (7.4%)
developed symptomatic DVT. The incidence for DVT was significantly higher in the seroconverted
patients compared with that of the non-seroconverted patients (odds ratio 5.5, 95%CI: 1.7–17.6 p
= 0.0028). Furthermore, in the patients with symptomatic DVT, the titer of HIT antibodies at post-
operative day 7 was significantly higher compared with those without symptomatic DVT.
Conclusion: Our data therefore suggest that seroconversion for HIT antibodies generated by
heparin is associated with a risk of DVT in patients undergoing total joint replacement.
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Background
Venous thromboembolism (VTE) is a common complica-
tion of surgical procedures. The risk for VTE in surgical
patients is determined by the combination of individual
predisposing factors and the specific type of surgery [1].
Patients undergoing major orthopedic surgery, which
includes hip and knee arthroplasty, are at particularly
high risk for VTE [2]. Postoperative DVT of the lower
limbs is often asymptomatic, and a fatal pulmonary
embolism (PE) may be the first clinical manifestation of
postoperative VTE [3]. Therefore, routine screening for
DVT of the lower limbs and early treatment are required.
In patients undergoing total joint replacement in the
absence of any prophylaxis, the incidence of venography-
detected DVT ranges from 42% to 57% in THA and 41%
to 85% in TKA [4], while that of clinically overt PE ranges
between 0.1% and 1.0% [5].
A number of anticoagulant-based regimens have been
evaluated for the prophylaxis of VTE in patients undergo-
ing joint replacement surgery. A randomized trial has
shown that prophylaxis with unfractionated heparin
(UFH) is more effective than no prophylaxis in patients
undergoing hip replacement [6]. Prophylaxis with UFH
reduces the occurrence of DVT, but has been associated
with an increased incidence of heparin-induced thrombo-
cytopenia (HIT) [7]. HIT is an adverse drug reaction
caused by the generation of an antibody against platelet
factor-4 (PF4) bound to heparin, which activates platelets
[8]. The frequency of HIT is about 3~5% in orthopedic
surgery patients treated with UFH [9]. However, the exact
role of HIT antibodies in DVT associated with orthopedic
surgery has not been fully elucidated. Recently, the pres-
ence of HIT antibodies has been reported to predict
adverse events in post-operative patients receiving
heparin [10]. In this study, we evaluated the levels of HIT
antibodies in patients undergoing THA or TKA under UFH
prophylaxis in relation to the DVT risk.
Methods
Patients
All patients who underwent primary TKA and primary
THA between September 1, 2006 and September 31, 2007
at our institution were enrolled in this study to determine
the incidence of PE and symptomatic DVT. In this study,
we enrolled 104 subjects (17 males and 87 females, 44
knee joints, 60 hip joints, age range 33–89 years, mean
age 68.0 years). The underlying disease was osteoarthritis
(OA) in 86 joints and rheumatoid arthritis (RA) in 18
joints (Table 1). All patients received 1000 units of UFH
via a single bolus intravenous injection during the opera-
tion and 5000 units of UFH via drip intravenous infusion
(24 hr) at post-operative day 2 after the operation. The
operation was performed under general anesthesia in all
cases. An extremity tourniquet was routinely used during
surgery to control blood loss in TKA. A foot pump (A-V
Impulse System, Novamedix Corp, Hampshire, UK) was
started on day 1 in all subjects. None of the patients had
any history of previous heparin exposure within the past
90 days. The study protocol was approved by the Ethics
Committees of the Nagasaki Medical Center and written
informed consent was obtained from each patient.
Blood sampling
Serum samples were collected before operation and at
postoperative day 7, and stored at -70°C. A sandwich
ELISA kit (GTI Diagnostics, Waukesha, WI) was used to
measure the anti-heparin-PE4 antibody (HIT Ab) titer of
the serum according to the manufacturer's instructions,
with the exception of the cut-off values. The microtiter
wells were precoated with polyvinylsulfonate-PF4 com-
plexes. Antibodies bound to polyvinylsulfonate-PF4 were
identified by affinity-purified anti-human IgG, IgA, or IgM
peroxidase conjugate. ELISA reactivities (optical density,
OD) are expressed relative to a standard control. Positive
and negative controls were included in every plate. The
samples with readings greater than or equal to 0.55
absorbance units (mean+2SD of 40 sera from Japanese
healthy subjects) were considered positive. Inhibition of a
positive reaction by 50% or more in the presence of excess
heparin was confirmed in all HIT antibody seroconverted
patients. While the results of the ELISA test merely con-
firm the presence of HIT antibodies, HIT was defined as a
>50% reduction in the platelet count or an absolute plate-
let count of < 10 × 104/ml during and after heparin treat-
ment, with no other cause of thrombocytopenia, and a
positive result in the HIT antibody test [11]. For measure-
ment of D-dimer, venous blood was collected in 5-mL
Vacutainer® tubes prefilled with 0.5 mL of 3.2% (0.105
mol/L) trisodium citrate-dihydrate. Specimens were cen-
trifuged at 1700 g for 15 minutes at room temperature. D-
Table 1: Patients characteristics
Type of surgery
Characteristics THA(n = 60) TKA(n = 44) p-value
Age (years), mean (SD) 63.1(12.1) 74.6(7.9) < 0.01
Gender (male/female) 8/52 9/35 0.33
BMI (Kg/m2), mean (SD) 24.3(4.0) 25.9(4.7) 0.13
Metabolic diseases, n(%) 20(33.3%) 23(52.3%) 0.05
Hypertension
Diabetes
Hyperlipidemia
History of thrombosis 0 1(2.3%) -
Primary diseases 8/52 10/34 0.26
(RA/OA)
DVT, deep vein thrombosis; SD, standard deviation; BMI, body mass 
index;
TKA, total knee arthroplasty; THA, total hip arthroplasty;
RA, rheumatoid arthritis; OA, osteoarthritis.BMC Musculoskeletal Disorders 2009, 10:42 http://www.biomedcentral.com/1471-2474/10/42
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dimer assays were performed according to the manufac-
turer's instructions on a CA-1500 automated coagulom-
eter (Sysmex, Kobe, Japan) using a commercial kit (Afresa
Pharma Co, Osaka, Japan).
Assessment of venous thromboembolism
The patients were clinically examined daily for signs and
symptoms of deep vein thrombosis, including pain, swell-
ing, redness of the legs and positivity for Homan's sign, or
pulmonary embolism until post-operative day 25-day 30.
If these were present, bilateral venography or contrast-
enhanced computed tomography were performed. Venog-
raphy or computed tomography was evaluated by an
independent panel of radiologists. The thrombi were clas-
sified as proximal if the popliteal or femoral veins were
involved and distal if only the calf veins were implicated.
Assessment of bleeding
During this study, the patients were examined daily for
any evidence of wound hematoma, as well as other man-
ifestations of bleeding. Bleeding was considered major if
there was a wound hematoma necessitating surgical revi-
sion, gastrointestinal bleeding, or any bleeding requiring
blood transfusion and interruption of prophylaxis.
Statistical analysis
A comparison of the variables in the two groups, with or
without DVT, was performed by Fisher's exact test or
Mann-Whitney U-test. We used Fisher's exact test to calcu-
late the 95% CI for the absolute difference and risk ratio
between patients with or without HIT antibodies.
Results
Postoperative outcome
No major bleeding complications were observed in any of
the 104 patients who underwent surgery, and no mortal-
ity occurred within the 3 post-operative months. No com-
plications were associated with the use of intraoperative
heparin or the pneumatic compression device, and none
of the patients developed symptomatic PE. Patients with
clinical symptoms or signs that would lead us to suspect
DVT were investigated using either contrast-enhanced CT
or venography. These examinations confirmed the clinical
diagnosis of symptomatic DVT in 16 patients (TKA; 10/
44, THA; 6/60). These DVT occurred during post-opera-
tive day5~day14. No proximal thrombi were noted in any
of the patients. The patient's preoperative profiles are
listed in Table 2. The profiles were similar in gender, lab-
oratory data, and risk factors in patients who were positive
or negative for post-operative symptomatic DVT,
although not for the patient age.
HIT antibody status
The HIT antibodies were present in 34.6% (36/104) of the
total patients. As shown in Table 3, the risk for postoper-
ative symptomatic DVT was significantly higher in
patients with HIT antibodies compared with those with-
out HIT antibodies (OR; 5.5; 95% CI 1.7–17.6). The over-
all HIT antibody optical densities were compared between
the patients with or without symptomatic DVT. No signif-
icant differences in the HIT antibody optical densities
before operation were noted between the patients with or
without symptomatic DVT. However, the patients with
symptomatic DVT demonstrated significantly higher HIT
antibody optical densities at post-operative day 7, com-
pared with those without symptomatic DVT (Figure 1).
There was no significant change in the platelet counts
(before operation versus post-operative day 7) in the
patients without HIT antibodies or in patients with HIT
antibodies (Figure 2). One patient developed a low plate-
let count ( < 10 × 104/ml). However, in this patient, no
seroconversion of HIT antibody was observed. We also
measured the coagulation marker, D-dimer, at postopera-
tive day 7. The values of D-dimer differed when samples
were separated into HIT antibody-positive and -negative
groups (Figure 3). In the HIT antibody-positive group, the
D-dimer values were significantly higher compared with
those in the HIT antibody-negative group (HIT antibody
(+); 21.5 ± 7.4 mg/ml versus HIT antibody (-); 17.5 ± 7.8
mg/ml). The preoperative clinical data were compared
between patients with or without seroconversion for HIT
antibody to identify the factors affecting seroconversion.
There were no differences in the preoperative clinical data
between the patients with or without HIT antibodies
(Table 4).
Discussion
Patients who have undergone orthopedic operations,
such as total joint replacement of the lower extremity, are
at high risk for thrombotic disease [1]. Without prophy-
Table 2: Patient characteristics and symptomatic DVT
Characteristics DVT(-)
n = 88
DVT(+)
n = 16
p-value
Age (years), mean (SD) 66.9 (12.5) 73.8 (5.4) 0.04
Gender (male/female) 16/72 1/15 0.24
BMI (Kg/m2), mean (SD) 24.9 (4.4) 25.7 (4.1) 0.42
Metabolic diseases, n(%) 36 (40.9) 7 (43.8) 0.83
Hypertension
Diabetes
Hyperlipidemia
History of thrombosis 0 1 (6.3) -
TKA/THA 46/42 10/6 0.08
Primary diseases 16/72 2/14 0.54
(RA/OA)
DVT, deep vein thrombosis; SD, standard deviation; BMI, body mass 
index;
TKA, total knee arthroplasty; THA, total hip arthroplasty;
RA, rheumatoid arthritis; OA, osteoarthritis.BMC Musculoskeletal Disorders 2009, 10:42 http://www.biomedcentral.com/1471-2474/10/42
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laxis after TKA, the prevalence of DVT has been 41% to
85% [4]. In this study, we attempted to lower the inci-
dence of DVT by combining a fixed dose of UFH with the
intermittent pneumatic compression device. We found
the incidence of symptomatic DVT after total joint
replacement to be 15.4% overall (16/104) with distal
(calf) thrombosis in all cases. The diagnosis of DVT is dif-
ficult in the absence of symptoms and consequently it is
often under-diagnosed. Venography is the gold standard
diagnostic method for DVT [12], but it is difficult to justify
its use as a screening tool in all at-risk patients due to its
invasive nature. The limitations of our study include the
performance rate of contrast-enhanced computed tomog-
raphy or venography, and only symptomatic DVT was sur-
veyed. Therefore, the incidence of DVT in the present
study cannot be compared to that of previous studies.
We could not confirm the association of DVT with under-
lying diseases, the location of the operation (knee or hip),
or the presence of a thrombotic risk factor. However, we
did find that the seroconversion of HIT antibody was sig-
nificantly higher in post-operative patients with sympto-
Table 3: Comparison of symptomatic DVT incidence rate between seroconverted and non-converted patients
Seroconverted Non-converted Odds ratio p-value
n = 36 n = 68 (95%CI)
(%) (%)
DVT incidence 11
(30.6%)
5
(7.4%)
5.5
(1.7–17.6%)
0.028
Median optical density (OD) of HIT antibodies before and after operation (post-operative day 7) in patients receiving joint  arthroplasty Figure 1
Median optical density (OD) of HIT antibodies before and after operation (post-operative day 7) in patients 
receiving joint arthroplasty. Box plots indicate the mean, interquartile rage (25%–75%) and outliers (min, max).BMC Musculoskeletal Disorders 2009, 10:42 http://www.biomedcentral.com/1471-2474/10/42
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matic DVT compared with those without symptomatic
DVT. The values of D-dimer at post-operative day 7 were
also significantly higher in patients with seroconversion
for HIT antibody compared with those without serocon-
version. These findings suggest that the presence of HIT
antibodies could be linked to platelet activation, as dem-
onstrated in vitro, [13] and that some patients having these
antibodies develop thrombotic manifestations.
Type II HIT is a prothrombotic adverse drug reaction
caused by platelet-activating antibodies that recognize
PF4 bound to heparin (anti-PF4/heparin antibody) [14].
The PF4 becomes immunogenic when it is bound to
heparin. Multi-molecular complexes of heparin, PF4, and
IgG bind to the platelet Fc receptors resulting in platelet
activation. Once these events are triggered, the prothrom-
botic risk remains for days to week, even after cessation of
heparin therapy [13]. Therefore, type II HIT is an impor-
tant adverse drug reaction induced by HIT antibodies that
causes venous and arterial thrombosis [15]. Case reports
and patient series have suggested that heparin-associated
Table 4: Patient characteristics and seroconversion of HIT Ab
Characteristics HIT Ab(-)
n = 68
HIT Ab(+)
n = 36
p-value
Age (years), mean (SD) 68.5 ± 11.8 66.9 ± 12.3 0.50
Gender (male/female) 13/55 4/32 0.29
BMI (Kg/m2), mean (SD) 24.62 ± 4.31 25.71 ± 4.42 0.29
Metabolic diseases, n(%) 30(44.1%) 13(36.1%) 0.43
Hypertension
Diabetes
Hyperlipidemia
History of thrombosis - 1(2.8%) -
TKA/THA 27/41 17/19 0.46
Primary disease 14/54 4/32 0.19
(RA/OA)
HIT Ab, Anti-heparin platelet factor-4 antibody SD, standard 
deviation;
BMI, body mass index; TKA, total knee arthroplasty; THA, total hip 
arthroplasty;
RA, rheumatoid arthritis; OA, osteoarthritis.
Changes of platelet counts during the joint replacement treatment Figure 2
Changes of platelet counts during the joint replacement treatment. Platelet counts before operation and post-oper-
ation (post-operative day 7) in each patients with or without seroconvertion of HIT antibodies were shown.BMC Musculoskeletal Disorders 2009, 10:42 http://www.biomedcentral.com/1471-2474/10/42
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thrombosis might occur in patients with detectable HIT
antibodies but in whom no thrombocytopenia is evident
[16-19]. These findings suggest that a subset of HIT anti-
bodies might exhibit a platelet activating profile without
inducing thrombocytopenia. While confirmation of the
presence of HIT antibodies is necessary, it is not sufficient
for diagnosis of HIT since antibody formation occurs in a
variety of clinical settings.
In HIT patients, the platelet counts begins to fall four or
more days after the start of heparin therapy (typically
between 5 and 10 days) [20]. Similarly, seroconversion of
HIT antibodies occurs 5 to 10 days after the initiation of
heparin therapy, except in patients with prior heparin
therapy [21]. Consistent with these previous findings, our
data demonstrated that seroconversion occurred in 34%
of patients undergoing total joint replacement one week
after the start of heparin. Our data suggest the clinical sig-
nificance of HIT antibodies in DVT risk after joint replace-
ment in the absence of thrombocytopenia.
A randomized clinical trial reported a significant differ-
ence in the occurrence of DVT between UFH and low
molecular weight heparin (LMWH) in post-operative
orthopedic patients [22-24]. More recently, a meta-analy-
sis demonstrated that fondaparinux showed a major ben-
efit by reducing VTE to a greater degree than LMWH in
patients undergoing orthopedic surgery [25]. It was
reported that HIT antibodies were generated at similar fre-
quencies in patients treated with fondaparinux or LMWH
[26]. However, in vitro, the antibodies induced by fonda-
parinux bind to PF4/LMWH and to PF4/UFHP, but not to
PF4/fondaparinux. The few PF4/fondaparinux/Ab com-
plexes are most likely inadequate to induce platelet activa-
tion via cross-linking [26]. The use of LMWH has not been
approved or recommended for the prophylaxis of throm-
boembolism in Japanese orthopedic patients. Fonda-
parinux is now approved for major orthopedic surgery in
Japan. Fondaparinux could be preferable to unfraction-
ated heparin for DVT prophylaxis in patients undergoing
total joint replacement. However, no evidence has yet
been found to conclude that fondaparinux is effective in
the prevention of VTE and is safe for Japanese orthopedics
patients, and additional research is needed to determine
the clinical benefit.
To summarize, in patients who undergo total hip or knee
replacement with the use of UFH, the seroconversion of
HIT antibodies contributes in part to the occurrence of
symptomatic DVT after surgery. The measurement of HIT
D-dimer values in plasma of patients with or without seroconvertion of HIT antibodies at post-operative day 7 Figure 3
D-dimer values in plasma of patients with or without seroconvertion of HIT antibodies at post-operative day 7. 
Box plots indicate the mean, interquartile rage (25%–75%) and outliers (min, max).BMC Musculoskeletal Disorders 2009, 10:42 http://www.biomedcentral.com/1471-2474/10/42
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antibodies is warranted to estimate the risk of throm-
boembolism in orthopedic patients undergoing total
joint replacement. Additional research is therefore needed
to clarify the relationship between VTE risk and HIT anti-
bodies in patients undergoing total joint replacement
with the new prophylactic anti-coagulants.
Conclusion
Seroconversion of HIT antibodies was associated with a
risk of symptomatic DVT in patients undergoing total
joint replacement under the prophylaxis of thromboem-
bolism using heparin.
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